Hims Review 2026: Wegovy, Finasteride & Men’s Health

Hims earns an Expert Score of 4.5/5.0 from BestGuide, establishing it as a leading telehealth platform for men’s health. This score reflects strong performance in treatment efficacy, platform usability, and product breadth, with particular strength in its post-March 2026 access to FDA-approved branded GLP-1 weight loss medications. For men seeking convenient and discreet access to prescription treatments, this Hims review finds the service to be a credible option backed by NYSE-listed corporate transparency and BBB Accreditation since 2018.

What is Hims? It is a direct-to-consumer telehealth platform that connects patients with U.S.-licensed medical providers across multiple verticals. The Hims men’s lineup covers weight loss (now with branded Wegovy, Ozempic, and Zepbound following the Novo Nordisk partnership), hair loss (finasteride and minoxidil), sexual health (sildenafil, tadalafil for erectile dysfunction), mental health (anxiety and depression medications), dermatology, and primary care. The platform operates on a subscription model with consultations conducted asynchronously through secure messaging rather than live video.

The service is designed for efficiency, replacing traditional doctor’s office visits with online intake forms and provider review typically completed within 24 to 72 hours. Hims does not accept insurance for most products, with the notable exception of branded GLP-1 weight loss medications acquired through the March 2026 Novo Nordisk partnership, which are now billable through commercial insurance and may be paired with the Novo Nordisk Savings Card. Compare Hims with other top-rated weight loss programs to see how it stacks up.

How Hims Works

The Hims platform streamlines access to medical care into a three-step digital process. The entire experience is designed to be completed from home, typically in under 30 minutes for the initial setup. Hims uses asynchronous (message-based) consultations as its primary model and does not require lab work prior to prescribing GLP-1 medications. For chronic conditions like hair loss or ED, providers may continue follow-ups through the same messaging channel.

Step 1: Online Health Assessment

A potential patient visits the Hims website and selects a health category, such as weight loss, hair loss, ED, or mental health. The user then completes a detailed online questionnaire about their medical history, symptoms, and lifestyle. This intake form takes approximately 10 to 15 minutes to complete and is designed to gather the information a provider would need to make an informed prescribing decision.

Step 2: Licensed Provider Review

Once the assessment is submitted, the information is forwarded to a U.S.-licensed physician or nurse practitioner for review. This review is asynchronous, meaning there is no live video call required. The medical provider evaluates the patient’s file, determines if they are a suitable candidate for treatment, and may follow up with clarifying questions via a secure messaging portal. Provider review is typically completed within 24 to 72 hours of submission.

Step 3: Prescription and Discreet Delivery

If a prescription is deemed clinically appropriate, the provider issues it electronically. Hims then ships the medication directly to the customer’s address in discreet, unbranded packaging. Shipping is typically free and takes 5 to 7 business days to arrive. The service operates on a subscription basis, with automatic refills shipped quarterly or monthly depending on the treatment plan.

Who Hims Is Best For

Hims is best for men seeking convenient, discreet, and predictable access to treatment for common health concerns like weight loss, hair loss, ED, and mental health. The platform is ideally suited for individuals who are comfortable with telehealth, do not require in-person examinations, and value transparent flat-rate pricing. For weight loss, Hims is most cost-effective for men with commercial insurance who can leverage the Novo Nordisk Savings Card (potentially reducing Wegovy costs to $0 to $25 per month). For hair loss and ED, the self-pay model offers transparent pricing that may be lower than out-of-pocket costs for traditional in-person care. Hims is not appropriate for men seeking medications outside the platform’s clinical criteria (e.g., GLP-1s require BMI of 30+ or BMI of 27+ with weight-related health condition), or for those who prefer live video consultations with their provider.

Hims Weight Loss Program

The Hims weight loss program is the platform’s flagship recent expansion and the focus of significant regulatory change in 2026. Following the March 9, 2026 settlement with Novo Nordisk, Hims transitioned from offering compounded semaglutide to becoming an authorized distribution partner for FDA-approved branded GLP-1 medications. Customers researching the Hims weight loss program in 2026 should understand this material shift.

March 2026 Novo Nordisk Settlement: What Changed

• February 2026: Hims & Hers launched a compounded oral semaglutide pill at $49 for the first month and $99 thereafter. The launch drew immediate federal regulatory scrutiny. The Department of Health and Human Services (HHS) referred Hims & Hers to the Department of Justice (DOJ) for potential violations of the Food, Drug & Cosmetics Act.
• March 9, 2026: Hims & Hers reached a settlement with Novo Nordisk (the patent holder for Wegovy and Ozempic). Under the agreement, Hims discontinued compounded semaglutide for new patients and became an authorized distribution channel for Novo Nordisk’s branded FDA-approved products. Novo Nordisk dismissed its patent infringement lawsuit. Hims also agreed to stop advertising compounded GLP-1 drugs.
• March 26, 2026: Hims launched access to branded Wegovy (all doses, including oral and injectable formulations) and Ozempic on its platform. Eli Lilly’s Zepbound (tirzepatide) is also available through a separate arrangement.
• Existing compounded patients: May continue on current protocols in limited circumstances, with full discontinuation expected by mid-2026. Hims plans to maintain limited compounded GLP-1 access for patients whose clinical needs cannot be met using commercially available FDA-approved options, based on provider determination.

Hims Weight Loss Program Pricing (2026)

The Hims weight loss program operates on a membership-plus-medication model. Pricing reflects the post-March 2026 transition to FDA-approved branded medications:

• Hims Weight Loss Membership: $39 for the first month, $149 per month thereafter (consultations, ongoing provider support, nutrition guidance, peer programs).
• Branded Oral Wegovy (semaglutide): $249 per month (self-pay).
• Branded Injectable Wegovy (all doses, including Wegovy HD 7.2mg): $299 per month (self-pay).
• Branded Zepbound (tirzepatide): $399 per month (self-pay).
• Ozempic (semaglutide for Type 2 diabetes; off-label for weight loss): Available based on independent provider clinical judgment.
• With commercial insurance + Novo Nordisk Savings Card: Eligible patients may pay $0 to $25 per month for Wegovy.

The minimum total monthly cost for a self-pay user on Oral Wegovy after the first month is approximately $398 ($149 membership + $249 medication). For uninsured patients on injectable Wegovy HD or Zepbound, total monthly costs reach $448 to $548. Membership does not include or guarantee a prescription and is billed separately from medication.

GLP-1 Eligibility Criteria

To qualify for GLP-1 medications through Hims, patients typically need a Body Mass Index (BMI) of 30 or greater, or a BMI of 27 or greater with a weight-related health condition (such as Type 2 diabetes, hypertension, or high cholesterol). Hims providers will not prescribe GLP-1s outside these clinical criteria. Hims uses asynchronous (message-based) consultations and does not require or order baseline lab work prior to prescribing GLP-1 medications; some clinicians consider baseline labs (kidney function, A1C, thyroid) important for safe prescribing, so patients may want to discuss with a primary care provider whether independent lab work is appropriate.

Hims Hair Loss

Hims was originally built around its hair loss treatment offering and remains one of the most established telehealth platforms for male pattern hair loss (androgenetic alopecia). The hair loss program offers FDA-approved generic medications prescribed via asynchronous consultation:

• Finasteride 1mg (generic Propecia): Oral medication; FDA-approved for male pattern hair loss. Per Kaufman et al. (1998) and follow-up studies, finasteride prevents further hair loss progression in approximately 83 to 86 percent of men when taken consistently over 2 years, with some users experiencing regrowth. Hair loss plans starting around $22 per month.
• Topical Minoxidil: FDA-approved topical solution; works through a different mechanism than finasteride.
• Combination products: Hims offers a topical finasteride + minoxidil spray and a flavored chewable for users who prefer alternatives to standard tablets.

Important safety note on finasteride: A small percentage of men (approximately 2 to 4 percent in clinical studies) experience sexual side effects including decreased libido, erectile dysfunction, or reduced semen volume. There are post-marketing reports of persistent sexual, mental, and physical side effects that continue after discontinuation, sometimes referred to as Post-Finasteride Syndrome (PFS). The FDA updated the finasteride label in 2011 and 2012 to reflect these reports. Prospective users should discuss the full risk-benefit profile with their prescribing provider.

Hims Sexual Health (ED Treatment)

Hims offers prescription PDE5 inhibitors for erectile dysfunction (ED) through its telehealth platform. Available medications include:

• Generic Sildenafil: Active ingredient in Viagra; FDA-approved for ED.
• Generic Tadalafil: Active ingredient in Cialis; FDA-approved for ED.
• Hard Mints (chewables): Combination formulations marketed as discrete alternatives to standard tablets.

ED medications through Hims can cost as low as $4 per dose for generic sildenafil at lower-frequency use cases, scaling up based on dosage and quantity. As with hair loss, the ED program operates on a subscription basis, with provider review typically completed within 24 to 72 hours. Patients with cardiovascular conditions, those taking nitrates, or those with other contraindications should disclose all medications during the intake to ensure safe prescribing.

Hims Mental Health and Primary Care

Hims offers mental health services including online therapy and prescription medication management for conditions like anxiety and depression. Mental health plans range from $25 to $85 per month depending on the level of service (medication only versus therapy plus medication). Hims also operates a primary care vertical for routine men’s health needs, dermatology services (acne, anti-aging), and a range of vitamin and supplement products.

Hims Standout Features

Hims differentiates itself in the telehealth market through several key features.

Comprehensive Men’s Health Platform: Unlike services that focus on a single issue, Hims offers a wide array of treatments under one digital roof, covering weight loss, hair loss, sexual health, mental health, dermatology, and primary care. This integrated approach allows users to manage multiple health needs within a single subscription and provider relationship.

FDA-Approved Branded GLP-1 Access (Post-Novo Nordisk Partnership): Following the March 2026 Novo Nordisk partnership, Hims provides telehealth access to FDA-approved Wegovy (injectable and oral, including Wegovy HD 7.2mg) and Ozempic, plus Eli Lilly’s Zepbound. This positions Hims as one of the largest authorized distribution channels for branded GLP-1 weight loss medications in the U.S. telehealth market.

Insurance Integration for GLP-1s: Branded GLP-1 medications through Hims are billable through commercial insurance. Combined with the Novo Nordisk Savings Card, eligible patients with commercial insurance may pay $0 to $25 per month for Wegovy, a meaningful advantage over self-pay-only telehealth competitors.

Evidence-Based Hair Loss Treatments: Hims built its reputation on FDA-approved hair loss medications. Finasteride and minoxidil are clinically proven generic options with decades of post-market data. The combination spray and chewable formulations provide flexibility for users who prefer alternatives to standard tablets.

Hims Pros and Cons

Is Hims Legit?

Yes, Hims is a legitimate telehealth company. Hims is the male-focused brand of Hims & Hers Health, Inc., a publicly traded company on the New York Stock Exchange (NYSE: HIMS) since 2021. The company was founded in 2017 (incorporated July 6, 2017; business started December 30, 2013 per BBB records) and is led by co-founder and CEO Andrew Dudum. Corporate headquarters at 2269 Chestnut St #523, San Francisco, CA 94123-2600.

As a medical service provider, Hims is compliant with HIPAA regulations to protect patient privacy. All medical consultations are conducted by U.S.-licensed and board-certified healthcare professionals. The company partners with licensed pharmacies in the United States to dispense medications.

Following the March 9, 2026 settlement with Novo Nordisk, Hims operates as an authorized distribution partner for FDA-approved branded GLP-1 medications. This is a material upgrade from the previous compounded model in terms of regulatory and quality assurance: FDA-approved branded drugs are individually reviewed by the FDA for ingredient identity, purity, potency, sterility, dose consistency, and clinical outcomes. Compounded medications (which Hims previously offered for GLP-1s) are prepared in state-licensed compounding pharmacies and are not individually FDA-approved; FDA oversight of compounded products is more limited than for branded drugs.

Consumers should be aware that Hims faced significant federal regulatory attention in early 2026. The Department of Health and Human Services referred Hims & Hers to the Department of Justice for potential violations of the Food, Drug & Cosmetics Act related to the compounded oral semaglutide launch in February 2026. The March 9, 2026 settlement with Novo Nordisk addressed these concerns by pivoting Hims to authorized FDA-approved product distribution and an agreement to stop advertising compounded GLP-1 drugs.

Hims BBB Rating and Accreditation

Hims operates under the BBB profile of its parent company, Hims & Hers Inc., registered with BBB serving the San Francisco Bay Area and Northern Coastal California. Key details from the BBB profile:

• BBB Rating: A+ (highest possible letter grade).
• BBB Accreditation: Accredited since February 22, 2018.
• BBB File Opened: January 29, 2018.
• Years in Business: 12 (Business Started December 30, 2013; Business Incorporated July 6, 2017).
• Total Complaints: 3,977 in the last 3 years; 1,083 closed in the last 12 months.
• Customer Reviews: 3.8 out of 5 stars across 7,324 reviews.
• Business Management: Andrew Dudum, CEO.
• BBB Customer Complaint Notice: Per BBB, complaints concentrate on issues with cancelling orders and refund requests. BBB recommends users review the Terms and Conditions (with special attention to Subscription Products and Services) and the Refund Policy before subscribing.
• Refund and Exchange Policy: Per the BBB profile, Hims & Hers states all sales are final, irrevocable, and not eligible for refund. Hims does not accept returns. Damaged or incorrect orders may be replaced.

The 3.8/5 customer review score across 7,324 reviews is a notably positive signal for a direct-to-consumer telehealth platform at this scale. For context, many large telehealth and consumer health companies see customer review scores below 1.5/5 on BBB. The A+ rating with BBB Accreditation since 2018 indicates BBB’s positive assessment of company responsiveness to filed complaints and adherence to BBB Standards for Trust. However, the volume of complaints (3,977 over 3 years) and the no-returns refund policy are material considerations for prospective subscribers.

Hims Cost: What You Should Expect to Pay

Hims operates on a transparent subscription pricing model. Most products are self-pay only (insurance not accepted), with the exception of branded GLP-1 weight loss medications acquired through the March 2026 Novo Nordisk partnership.

For weight loss, the minimum total monthly cost for a self-pay user on Oral Wegovy after the first month is approximately $398 ($149 membership + $249 medication). For uninsured patients on injectable Wegovy or Zepbound, total monthly costs reach $448 to $548. Eligible patients with commercial insurance and the Novo Nordisk Savings Card may see total costs as low as $149 to $174 per month.

Final Verdict: Hims Review

Hims earns an Expert Score of 4.5/5.0 from BestGuide. It stands out as a premier telehealth platform for men’s health, with particular strengths in its post-March 2026 access to FDA-approved branded GLP-1 weight loss medications and its long-established hair loss program built on FDA-approved generics like finasteride and minoxidil. The BBB A+ Accredited status (since 2018) and 3.8/5 customer review score across 7,324 reviews provide solid trust signals at scale, and NYSE-listed corporate transparency adds financial accountability. The platform’s recent Novo Nordisk partnership upgrade adds material regulatory and quality assurance to the weight loss vertical that was previously based on compounded products.

The score reflects several considerations that prevent a higher rating. First, the post-compounding pricing structure makes the weight loss program meaningfully more expensive for uninsured patients ($398 to $548 per month all-in versus the discontinued $79 to $228 compounded options). Second, the BBB profile shows 3,977 complaints over 3 years concentrated on subscription cancellation and refund issues, combined with a no-returns refund policy that limits consumer recourse. Third, Hims uses asynchronous consultations rather than video visits and does not require baseline lab work prior to prescribing GLP-1s, which some clinicians consider important for safe medical management. Finally, the early 2026 HHS referral to the DOJ over the compounded GLP-1 launch, while resolved by the March 9, 2026 Novo Nordisk settlement, is part of the company’s recent regulatory profile that prospective customers may want to consider.

For men with commercial insurance who can leverage the Novo Nordisk Savings Card for weight loss, or for those seeking convenient access to FDA-approved hair loss generics like finasteride and minoxidil at transparent prices, Hims is a legitimate and competitive option. Self-pay weight loss patients should compare total monthly costs against alternatives before subscribing. As with any prescription medication, patients should consult with a healthcare provider and consider the full risk-benefit profile, including potential side effects (GI symptoms common for GLP-1s; potential sexual side effects for finasteride including rare post-discontinuation persistence; cardiovascular contraindications for PDE5 inhibitors).

See our full Buyers Guide for the best weight loss programs before making your decision.

Frequently Asked Questions About Hims

What do experts say about Hims?
BestGuide gives Hims an Expert Score of 4.5 out of 5.0. Experts praise the post-March 2026 access to FDA-approved branded Wegovy, Ozempic, and Zepbound through its Novo Nordisk distribution partnership, the long-established FDA-approved hair loss generics, and the 3.8/5 customer review score across 7,324 BBB reviews. Main critiques: higher self-pay medication costs since discontinuation of compounded semaglutide, async-only consultations, no-returns refund policy, and federal regulatory scrutiny in early 2026 over the compounded GLP-1 launch.

Is Hims worth it in 2026?
For men seeking discreet, convenient telehealth access for common men’s health concerns (weight loss, hair loss, ED, mental health), Hims is worth considering. For weight loss specifically, the value proposition is strongest for men with commercial insurance who can leverage the Novo Nordisk Savings Card (potentially $0 to $25/month medication). Self-pay weight loss patients should compare alternatives given $398 to $548 all-in monthly costs. For hair loss and ED, the transparent self-pay model offers predictable pricing.

How does Hims compare to other weight loss programs?
Hims is a telehealth platform offering FDA-approved GLP-1 medications. It differs from behavioral programs like Noom or diet-based plans like Weight Watchers in that Hims focuses on medical intervention with prescription drugs. Within telehealth GLP-1, Hims competes with Ro, Henry Meds, Found Health, and direct providers like LillyDirect. Hims’ main differentiation post-March 2026 is its Novo Nordisk authorized partnership and insurance integration.

Does Hims really work?
Hims treatments are based on FDA-approved medications with clinical evidence. For GLP-1s, STEP-1 trial data for semaglutide 2.4mg (Wegovy) showed average 14.9% body weight loss over 68 weeks combined with diet and exercise. Newer Wegovy HD 7.2mg studies showed mean weight loss of approximately 20.7%, with dysesthesia (abnormal skin sensation) in 18.9% of patients. For hair loss, finasteride prevents further hair loss progression in approximately 83 to 86 percent of men when taken consistently over 2 years per Kaufman et al. (1998) and follow-up studies. Individual results vary; discontinuing medication may result in regression.

What is the Hims weight loss program?
The Hims weight loss program provides medical consultations and prescriptions for FDA-approved branded GLP-1 medications, including Wegovy (oral and injectable, including Wegovy HD 7.2mg), Ozempic, and Eli Lilly’s Zepbound. Following the March 9, 2026 Novo Nordisk settlement, Hims discontinued compounded semaglutide for new patients. Membership is $39 for the first month and $149 per month thereafter. Self-pay medication costs range from $249 to $399 per month; eligible patients with commercial insurance and the Novo Nordisk Savings Card may pay $0 to $25 per month.

What happened to the Hims compounded semaglutide?
In February 2026, Hims launched a compounded oral semaglutide pill at $49 for the first month. HHS referred Hims & Hers to the DOJ for potential Food, Drug & Cosmetics Act violations. On March 9, 2026, Hims & Hers settled with Novo Nordisk, dismissing the patent infringement lawsuit and agreeing to discontinue compounded semaglutide for new patients and stop advertising compounded GLP-1 drugs. Hims now operates as an authorized distribution partner for branded FDA-approved Wegovy and Ozempic. Limited compounded access may remain available for patients whose clinical needs cannot be met using commercially available FDA-approved products, per provider determination.

How much does Hims cost?
Costs vary by treatment category. Weight loss: $39 first month ($149 thereafter) membership plus medication ($249-$399/month self-pay or $0-$25 with insurance + Savings Card). Hair loss: starting around $22/month. ED: as low as $4 per dose for generic sildenafil. Mental health: $25 to $85/month depending on service level.

Does Hims take insurance?
Hims accepts commercial insurance only for branded GLP-1 weight loss medications acquired through the March 2026 Novo Nordisk partnership (Wegovy, Ozempic). All other Hims products (hair loss, ED, mental health, compounded medications) remain self-pay only. Hair loss and ED users should expect to pay out-of-pocket at the listed subscription rates.

Does Hims hair loss work?
Hims prescribes FDA-approved finasteride and minoxidil for male pattern hair loss. Per Kaufman et al. (1998) and subsequent studies, finasteride prevents further hair loss progression in approximately 83 to 86 percent of men when taken consistently over 2 years. Some users also experience modest regrowth. Individual results vary and discontinuation typically results in loss of benefits over 9 to 12 months. A small percentage of users (approximately 2 to 4 percent) report sexual side effects; there are post-marketing reports of persistent side effects after discontinuation (Post-Finasteride Syndrome). Discuss the full risk-benefit profile with your prescribing provider.

Is Hims legit and safe?
Yes, Hims is a legitimate company. It is publicly traded (NYSE: HIMS), uses U.S.-licensed physicians for consultations, and prescribes FDA-approved medications dispensed by licensed pharmacies. The parent company holds a BBB A+ rating with BBB Accreditation since February 22, 2018. Consumers should be aware of the early 2026 HHS DOJ referral over the compounded GLP-1 launch, which was resolved by the March 9, 2026 Novo Nordisk settlement.

What is the Hims refund policy?
Per the parent company’s BBB-listed policy, all sales are final, irrevocable, and not eligible for refund. Hims does not accept returns. Damaged or incorrect orders may be replaced. Review the full Terms and Conditions and Refund Policy on the Hims website before subscribing, especially the Subscription Products and Services section per BBB’s recommendation.

Who owns Hims?
Hims is the male-focused brand of Hims & Hers Health, Inc., publicly traded on the New York Stock Exchange (NYSE: HIMS) since 2021. Led by co-founder and CEO Andrew Dudum. Headquartered at 2269 Chestnut St #523, San Francisco, CA 94123-2600. Hers is the female-focused sister brand under the same parent company.